Effect of Home-Based Pulmonary Rehabilitation on Pulmonary Fibrosis
Keywords:
home-based pulmonary rehabilitation, Post-Covid pulmonary fibrosis, idiopathic pulmonary fibrosis, interstitial lung disease, pulmonary function test, Quality of lifeAbstract
Background: Pulmonary fibrosis is a chronic, progressive lung condition that involves lung tissue scarring and thickening. The effects of home-based pulmonary rehabilitation (PR) in post-covid pulmonary fibrosis (PCPF) and other forms of fibrosis together have not been evaluated. This study aims to evaluate the effectiveness of home-based pulmonary rehabilitation on pulmonary function, functional capacity, and health-related quality of life in people with pulmonary fibrosis (post-COVID pulmonary fibrosis, pulmonary fibrosis secondary to pulmonary tuberculosis (TB), pulmonary fibrosis secondary to interstitial lung disease (ILD), pulmonary fibrosis secondary to bronchiectasis).
Methods: A single-group pretest–posttest experimental study was performed after recruiting 98 pulmonary fibrosis subjects from K.M.C hospitals. After being screened for the inclusion and exclusion criteria, 45 subjects were analyzed, and 6 subjects were lost to follow-up. A home-based pulmonary rehabilitation program was carried out for 8 weeks (warm-up, stretching exercises, aerobic exercise, strength training for upper limb and lower limb, breathing exercises mainly involved; others: energy saving techniques, controlled coughing techniques, dyspnea relieving positions). The program was supervised via weekly phone calls. Pulmonary function (Pulmonary function test), exercise capacity (6-minute walk test), dyspnea (modified Borg scale), and health-related quality of life (SF-36) were evaluated before and after the intervention. During the enrollment and after the 6-minute walk test, saturation of peripheral oxygen (SPO2) level was also evaluated pre-intervention and after the 8-weeks program.
Results: Pulmonary function [FVC(L) t = -12.52, p<0.05; FEV1(L) t = -2.56, p<0.05; FEV1/FVC t = 7.98, p<0.05 and DLCO (ml/min/mmHg) t = -5.13, p<0.05], 6MWD [MD 88.66; p<0.05] and HRQOL measured by SF-36 scores (p<0.05) were improved significantly. Both the baseline SPO2 level before the 6MWT [MD 1.07, p<0.05] and the SPO2 level after the 6MWT [MD 1.16, p<0.05] showed a significant improvement. The rating of perceived exertion(dyspnea) [MD 1.30, p<0.05] was reduced significantly after the 8-week program.
Conclusion: Our study shows that home-based pulmonary rehabilitation is an effective option for improving lung function and physical functional capacity by reducing dyspnea perception and improving the saturation of peripheral oxygen (SPO2) level, and enhancing the quality of life in people with pulmonary fibrosis.
References
Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Antoniou KM, Bissell BD, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 2022;205(9):E18–47.
Nashatyreva MS, Trofimenko IN, Chernyak BA, Avdeev SN. Pulmonary Fibrosis and Progressive Pulmonary Fibrosis in a Prospective Registry of Interstitial Lung Diseases in Eastern Siberia. Life 2023;13(1):1–11.
Tran S, Ksajikian A, Overbey J, Li P, Li Y. Pathophysiology of Pulmonary Fibrosis in the Context of COVID-19 and Implications for Treatment: A Narrative Review. Cells 2022;11(16):1–10.
Maher TM, Bendstrup E, Dron L, Langley J, Smith G, Khalid JM, et al. Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res [Internet] 2021;22(1):1–10. Available from: https://doi.org/10.1186/s12931-021-01791-z
Oronsky B, Larson C, Hammond TC, Oronsky A, Kesari S, Lybeck M, et al. A Review of Persistent Post-COVID Syndrome (PPCS). Clin Rev Allergy Immunol [Internet] 2023;64(1):66–74. Available from: https://doi.org/10.1007/s12016-021-08848-3
Ambardar SR, Hightower SL, Huprikar NA, Chung KK, Singhal A, Collen JF. Post-COVID-19 pulmonary fibrosis: Novel sequelae of the current pandemic. Vol. 10, Journal of Clinical Medicine MDPI 2021.
Meyerholz DK. Rigid respiration: fulminant pulmonary fibrosis after COVID-19. eBioMedicine [Internet] 2023;87(December 2022):104428. Available from: https://doi.org/10.1016/j.ebiom.2022.104428
Oatis D, Simon-Repolski E, Balta C, Mihu A, Pieretti G, Alfano R, et al. Cellular and Molecular Mechanism of Pulmonary Fibrosis Post-COVID-19: Focus on Galectin-1, -3, -8, -9. Int J Mol Sci 2022;23(15).
Hirawat R, Jain N, Aslam Saifi M, Rachamalla M, Godugu C. Lung fibrosis: Post-COVID-19 complications and evidences. Int Immunopharmacol [Internet] 2023;116(November 2022):109418. Available from: https://doi.org/10.1016/j.intimp.2022.109418
Ozalevli S, Karaali HK, Ilgin D, Ucan ES. Effect of home-based pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Multidiscip Respir Med 2010;5(1):31–7.
Singh SJ, ZuWallack RL, Garvey C, Spruit MA, Brindicci C, Higenbottam T, et al. Learn from the past and create the future: The 2013 ATS/ERS statement on pulmonary rehabilitation Eur Respir J 2013;42(5):1169–74.
Holland AE, Singh SJ, Casaburi R, Clini E, Cox NS, Galwicki M, et al. Defining modern pulmonary rehabilitation: An official American thoracic society workshop report. Ann Am Thorac Soc 2021;18(5):E12–29.
Ranaweera A. American Thoracic Society. Int J Pharm Med 2005;19(3):173–7.
Uzzaman MN, Agarwal D, Chan SC, Engkasan JP, Habib GMM, Hanafi NS, et al. Effectiveness of home-based pulmonary rehabilitation: systematic review and meta-analysis. Eur Respir Rev [Internet] 2022;31(165). Available from: http://dx.doi.org/10.1183/16000617.0076-2022
Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis An Official ATS/ERS/JRS/ALAT Clinical practice guideline. Am J Respir Crit Care Med 2018;198(5):e44–68.
Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, et al. American thoracic society/European respiratory society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 2006;173(12):1390–413.
Rochester CL, Vogiatzis I, Holland AE, Lareau SC, Marciniuk DD, Puhan MA, et al. An official American Thoracic Society/European Respiratory Society policy statement: Enhancing implementation, use, and delivery of pulmonary rehabilitation. Am J Respir Crit Care Med 2015;192(11):1373–86.
José A, Holland AE, Selman JPR, Camargo CO De, Fonseca DS, Athanazio RA, et al. Home-based pulmonary rehabilitation in people with bronchiectasis : a randomised controlled trial 2021;(March). Available from: http://dx.doi.org/10.1183/23120541.00021-2021
Shen L, Zhang Y, Su Y, Weng D, Zhang F, Wu Q, et al. New pulmonary rehabilitation exercise for pulmonary fibrosis to improve the pulmonary function and quality of life of patients with idiopathic pulmonary fibrosis: A randomized control trial. Ann Palliat Med 2021 Jul 1;10(7):7289–97.
Graham BL, Steenbruggen I, Barjaktarevic IZ, Cooper BG, Hall GL, Hallstrand TS, et al. Standardization of spirometry 2019 update an official American Thoracic Society and European Respiratory Society technical statement. Am J Respir Crit Care Med 2019;200(8):E70–88.
Issues S, Test MW, Equipment R, Preparation P. American Thoracic Society ATS Statement : Guidelines for the Six-Minute Walk Test 2002;166:111–7.
Williams N. The Borg Rating of Perceived Exertion (RPE) scale. Occup Med (Chic Ill) 2017;67(5):404–5.
Lins L, Carvalho FM. SF-36 total score as a single measure of health-related quality of life: Scoping review. SAGE Open Med 2016;4:205031211667172.
Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 statement: Extension to randomised pilot and feasibility trials. BMJ 2016;355.
Lancaster GA. Guideliens for reporting non randomised 2019;1:1–6.
Puente-Maestu L, Palange P, Casaburi R, Laveneziana P, Maltais F, Neder JA, et al. Use of exercise testing in the evaluation of interventional efficacy: An official ERS statement. Eur Respir J [Internet] 2016;47(2):429–60. Available from: http://dx.doi.org/10.1183/13993003.00745-2015
Spielmanns M, Pekacka-Egli AM, Schoendorf S, Windisch W, Hermann M. Effects of a comprehensive pulmonary rehabilitation in severe post-covid-19 patients. Int J Environ Res Public Health 2021 Mar 1;18(5):1–14.
Singh SK, Naaraayan A, Acharya P, Menon B, Bansal V, Jesmajian S. Pulmonary Rehabilitation in Patients with Chronic Lung Impairment from Pulmonary Tuberculosis. Cureus 2018;10(11).
Sala E, Roca J, Marrades RM, Alonso J, Gonzalez De Suso JM, Moreno A, et al. Effects of endurance training on skeletal muscle bioenergetics in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;159(6):1726–34.
Jahn K, Sava M, Sommer G, Schumann DM, Bassetti S, Siegemund M, et al. Exercise capacity impairment after COVID-19 pneumonia is mainly caused by deconditioning. Eur Respir J 2022;59(1).
Jolley SE, Bunnell AE, Hough CL. ICU-Acquired Weakness. Chest [Internet] 2016;150(5):1129–40. Available from: http://dx.doi.org/10.1016/j.chest 2016.03.045
Spruit MA, Thomeer MJ, Gosselink R, Troosters T, Kasran A, Debrock A, et al. Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax 2005;60(1):32–8.
Watanabe F, Taniguchi H, Sakamoto K, Kondoh Y, Kimura T, Kataoka K, et al. Quadriceps weakness contributes to exercise capacity in nonspecific interstitial pneumonia. Respir Med [Internet] 2013;107(4):622–8. Available from: http://dx.doi.org/10.1016/j.rmed.2012.12.013
Hanada M, Kasawara KT, Mathur S, Rozenberg D, Kozu R, Ahmed Hassan S, et al. Aerobic and breathing exercises improve dyspnea, exercise capacity and quality of life in idiopathic pulmonary fibrosis patients: Systematic review and meta-analysis. J Thorac Dis 2020;12(3):1041–55.
Gomes-Neto M, Silva CM, Ezequiel D, Conceição CS, Saquetto M, MacHado AS. Impact of Pulmonary Rehabilitation on Exercise Tolerance and Quality of Life in Patients with Idiopathic Pulmonary Fibrosis A SYSTEMATIC REVIEW and META-ANALYSIS. J Cardiopulm Rehabil Prev 2018;38(5):273–8.
Gloeckl R, Leitl D, Jarosch I, Schneeberger T, Nell C, Stenzel N, et al. Benefits of pulmonary rehabilitation in COVID-19: a prospective observational cohort study. ERJ Open Res 2021 Apr;7(2):00108–2021.
Yu X, Li X, Wang L, Liu R, Xie Y, Li S, et al. Pulmonary Rehabilitation for Exercise Tolerance and Quality of Life in IPF Patients: A Systematic Review and Meta-Analysis. Biomed Res Int 2019;2019.
Ries AL. Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale. COPD J Chronic Obstr Pulm Dis 2005;2(1):105–10.
Rogliani P, Calzetta L, Coppola A, Puxeddu E, Sergiacomi G, D’Amato D, et al. Are there pulmonary sequelae in patients recovering from COVID-19? Vol. 21, Respiratory Research. BioMed Central Ltd 2020.
Gigliotti F, Coli C, Bianchi R, Romagnoli I, Lanini B, Binazzi B, et al. Exercise training improves exertional dyspnea in patients with COPD: Evidence of the role of mechanical factors. Chest 2003;123(6):1794–802.
Cook H, Reilly CC, Rafferty GF. A home-based lower limb-specific resistance training programme for patients with copd: An explorative feasibility study. ERJ Open Res 2019;5(2).
Holland AE, Hill CJ, Conron M, Munro P, McDonald CF. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax 2008;63(6):549–54.
Nishiyama O, Taniguchi H, Kondoh Y, Kimura T, Ogawa T, Watanabe F, et al. Quadriceps weakness is related to exercise capacity in idiopathic pulmonary fibrosis. Chest [Internet] 2005;127(6):2028–33. Available from: http://dx.doi.org/10.1378/chest.127.6.2028
Bernard S, Leblanc P, Whittom F, Carrier G, Jobin J, Belleau R, et al. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;158(2):629–34.
Seymour JM, Spruit MA, Hopkinson NS, Natanek SA, Man WDC, Jackson A, et al. The prevalence of quadriceps weakness in COPD and the relationship with disease severity. Eur Respir J 2010;36(1):81–8.
Cox IA, Arriagada NB, De Graaff B, Corte TJ, Glaspole I, Lartey S, et al. Health-related quality of life of patients with idiopathic pulmonary fibrosis: A systematic review and meta-analysis. Eur Respir Rev [Internet] 2020;29(158):1–22. Available from: http://dx.doi.org/10.1183/16000617.0154-2020
Swigris J, Olson AL, Brown K. Understanding and optimizing health-related quality of life and physical functional capacity in idiopathic pulmonary fibrosis. Patient Relat Outcome Meas 2016;29.
Wallaert B, Duthoit L, Drumez E, Behal H, Wemeau L, Chenivesse C, et al. Long-term evaluation of home-based pulmonary rehabilitation in patients with fibrotic idiopathic interstitial pneumonias. ERJ Open Res [Internet] 2019;5(2). Available from: http://dx.doi.org/10.1183/23120541.00045-2019
Vainshelboim B. Exercise training in idiopathic pulmonary fibrosis: Is it of benefit? Breathe 2016;12(2):130–8.
Essam H, Wahab NHA, Younis G, El-Sayed E, Shafiek H. Effects of different exercise training programs on the functional performance in fibrosing interstitial lung diseases: A randomized trial. PLoS One [Internet] 2022;17(5 May):1–14. Available from: http://dx.doi.org/10.1371/journal.pone.0268589
Published
Issue
Section
License
Copyright (c) 2024 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Mattioli 1885 has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
How to Cite
